Coulter Partners places Dr. Ferenc Tracik as Chief Medical Officer of Neumirna Therapeutics

Neumirna Therapeutics is a biotechnology company dedicated to developing RNA-based therapies for complex neurological diseases.

Dr. Tracik is a physician-leader with more than two decades of expertise in neurological and rare disease drug development. At Neumirna, he will oversee medical and clinical strategy, focusing on patient safety, regulatory interactions, and external medical affairs. He will partner with Neumirna’s CDO to guide lead program NMT.001 into the clinic in early 2027 and lend his clinical perspective to Neumirna’s preclinical program in Parkinson’s disease.

Ellen Donnelly, CEO of Neumirna Therapeutics, commented: “Neumirna has reached an inflection point: the question is no longer whether the science works, but how quickly we can translate it into an option for patients with urgent unmet need. Ferenc has the experience to get us there. Alongside his leadership in CNS development and global regulatory strategy, he has played a key role in bringing an ASO therapy for a neurological disease to patients.

“We truly valued the partnership and strategic insight provided by Coulter Partners throughout this search. Their deep understanding of the ASO and RNA landscape allowed them to move with precision, identifying a CMO who possesses both the technical depth and the commercial launch experience necessary for our next phase of growth.”

Nanna Soni, Client Partner at Coulter Partners, added: “It was a great pleasure to support Neumirna during this critical phase of their transition toward the clinic. The technology represents the next frontier in treating drug-resistant epilepsy and other complex neuro-disorders, and identifying a physician-leader like Ferenc was critical. He is uniquely qualified to help bridge the gap between Neumirna’s pioneering research and transformative patient care. Our collaboration with CEO Ellen Donnelly and her deeply committed board resulted in a seamless and highly productive search process for this pivotal role.”
---

Dr. Ferenc Tracik, Chief Medical Officer, Neumirna Therapeutics

Dr. Tracik is a physician with more than 20 years of experience leading drug development programs in neurological and rare diseases. Most recently, as CMO at NeuroSense Therapeutics, he led global Phase 2 programs in ALS and Alzheimer’s disease, including a successful IND submission to the FDA.

Previously, Dr. Tracik served as Vice President, Europe, Canada, and Partner Markets at Biogen, where he led the European medical launch of an antisense oligonucleotide (ASO) for Spinal Muscular Atrophy (SMA). During his tenure at Biogen, he established a highly recognized multinational SMA registry in collaboration with leading experts and contributed to one of the largest global Expanded Access Programs in SMA. His career also includes significant leadership roles at Novartis and Teva.

Dr. Tracik holds an MD from Universität Regensburg, where his doctoral research focused on sleep disturbances in Parkinson's disease.

About Neumirna Therapeutics

About Coulter Partners